

Power up dispersion with 90% active load

LipiSpense® is an advanced cold water dispersion (CWD) technology, specifically designed to dramatically increase bioavailability and functionality of lipophilic actives in powder or crystalline form.

Multi award winning, patented technology, developed and made in Australia.

Often improving bioavailability by using standard methods leads to decreased active loads in final formulations. However, LipiSpense®'s superior performance means only 10% LipiSpense® is required with an impressive 90% active load, the largest amount of active/nutrient ratio in a water dispersible formulation.



IMPROVED FUNCTIONALITY


You are now able to include lipophilic actives in interesting /exciting format options. Oral gels, drops, functional foods /drinks, gummies are all dosage formats that are now achievable. High growth categories are charging forward with product formats needing high quality water dispersible powders. LipiSpense® powders allow you to create innovative formulations by adding nutrients previously not possible.

Ingredients powered by LipiSpense® can now be formulated in:

- Powdered drinks.
- Effervescent tablets.
- High bioavailable formulas.
- Direct in mouth powder sachets.
- Drinks, liquids, shots and gels.
- Functional foods and drinks.

INNOVATIVE TECHNOLOGY

LipiSpense® coats the active lipophilic (oil loving) crystals and transforms their surface into a hydrophilic (water loving) area. This property allows the LipiSpense® coated crystal to now easily disperse in water which, in turn, increases the body's ability to absorb it. LipiSpense® also offers protection to the acidic environment of the stomach, allowing it to avoid immediate breakdown.



REIMAGINE BIOAVAILABILITY

Significant increase in bioavailability of various lipophilic actives powered by LipiSpense® have been proven in multiple pharmacokinetic studies and published in high impact factor journals. Demonstrated superior absorption results are available for curcumin (HydroCurc®), resveratrol (Veri•Spense®) and PEA (Levagen®+).

LipiSpense® in action 60 second dispersion



Multi-award winning, supported by pharmacokinetic and clinical studies published in high impact journals, with a raft of continuing clinical studies under way.

- 1 PK Study - HydroCurc®:** Increased bioavailability of curcumin using a novel dispersion technology system (LipiSpense®). Briskey D., Sax A., Mallard AR., Rao A. Eur J Nutr. 2019 Aug;58(5): 2087-2097. doi.org/10.1007/s00394-018-1766-2
- 2 PK Study - Levagen®+:** Increased absorption of Palmitoylethanolamide using a novel dispersion technology System (LipiSpense®). Briskey D, Mallard A, Rao A J. Nutraceuticals Food Sci Vol.5 No.2:3. (2020). DOI: 10.36648/nutraceuticals.5.2.3
- 3. PK Study - Veri • Spense®:** Trans-Resveratrol oral bioavailability in humans using LipiSpense® dispersion technology. Briskey D, Rao. Pharmaceutics 2020, 12, 1190. doi.org/10.3390/pharmaceutics12121190
- 4 Clinical Trial - DOMS study HydroCurc®:** Curcumin improves delayed onset muscle soreness and post-exercise lactate accumulation. Mallard A, Briskey D, Richards A, et al. Journal of Dietary Supplements.(2020). doi.org/10.1080/19390211.2020.1796885
- 5 Clinical Trial - Exercise study Levagen®+:** The effect of orally dosed Levagen® + (palmitoylethanolamide) on exercise recovery in healthy males. Mallard A, Briskey D, Richards A, et al. Nutrients 2020, 12, 596; (2020). doi.org/10.3390/nu12030596
- 6 Clinical Trial - Joint pain Levagen®+:** The effect of a dispersible palmitoylethanolamide (Levagen®+) compared to a placebo for reducing joint pain in an adult population. Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. Inflammopharmacology 2019 Jun;27(3): 475-485. doi.org/10.11648/j.jinfs.20211001.12
- 7 BDNF Study - HydroCurc®:** Co-administration of iron and a bioavailable curcumin supplement increases serum BDNF levels in healthy adults. Lorinczova HT, Fitzsimons O, et al. Antioxidants 2020, 9, 645; (2020). doi.org/10.3390/antiox9080645
- 8 Iron Study - HydroCurc® + Iron:** Acute administration of bioavailable curcumin alongside ferrous sulphate supplements does not impair iron absorption in healthy adults in a randomised trial. Lorinczova HT, Begum G, Renshaw D, Zariwala, MG. Nutrients 2021,13 (7), 2300. doi.org/10.3390/nu13072300
- 9 Inflammation Study - HydroCurc® + Iron:** Co-administration of iron and bioavailable curcumin reduces levels of systemic markers of inflammation and oxidative stress in a placebo-controlled randomised study. Tiekou Lorinczova H, Begum G, Temouri L, Renshaw D, Zariwala MG. Nutrients. 2022; 14(3):712. doi.org/10.3390/nu14030712
- 10 Joint Study - HydroCurc®:** The effect of a dispersible curcumin (HydroCurc®) compared to a placebo for reducing joint pain in an adult population - a randomised, double-blind study. Briskey D, Roche G, Rao A. Complement Med Res. 2022;29(6):429-436. doi.org/10.1159/000524689
- 11 Covid-19 Study - HydroCurc®** Curcumin confers anti-inflammatory effects in adults who recovered from COVID-19 and were subsequently vaccinated: a randomized controlled trial. Fessler SN, Chang Y, Liu L, Johnston CS. Nutrients. 2023; 15(7):1548. doi.org/10.3390/nu15071548
- 12 Sleep Study - Levagen®+:** Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study. Rao A, Ebeft P, Mallard A, Briskey D. Sleep Sci Pract. 2021;5(1):12. doi.org/10.1186/s41606-021-00065-3
- 13 Joint/Knee Pain Study - Levagen®+:** A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Steels E, Venkatesh R, Steels E, Vitetta G, Vitetta L. Inflammopharmacology. 2019;27(3):475-485. doi.org/10.1007/s10787-019-00582-9
- 14 Lifestyle Management - Levagen®+:** Palmitoylethanolamide: A natural compound for health management. Clayton P, Hill M, Bogoda N,Subah S,Venkatesh R. Int J Mol Sci.2021;22 (10):5305. doi.org/10.3390/ijms22105305
- 15 Covid Study - Levagen®+:** Effects of Palmitoylethanolamide on proinflammatory markers in adults recently diagnosed with COVID-19. Samantha Fessler, Yung Chang, Carol Johnston, Li Liu. Current Developments in Nutrition, Volume 6, Supplement 1,2022. doi.org/10.1093/cdnznac048.014

AWARDS



2022 Europe
HydroCurc®
Ingredient of the Year
for Sports Nutrition

2022 USA
HydroCurc®
Ingredient of the Year
for Sports Nutrition

2021 Asia
HydroCurc®
Sporting Ingredient
of the Year

2020 Asia
HydroCurc®
Ingredient of the Year
for Cognitive Function

2019 Asia
LipiSpense®
Research Project of the Year

2019 Asia
LipiSpense®
Innovation of the Year

2018 Asia
HydroCurc®
Botanical Product of the Year



2022 Australia
International Health Winner



2020 HydroCurc®
Best Sports Nutrition Ingredient

2019 LipiSpense®
Most Innovative Idea



2022 Australia
Wholesale Distributor of the Year

2021 Australia
Quality Raw Material Supplier
of the Year

2018 Australia
Quality Raw Material Supplier
of the Year

Applying LipiSpense® trademarks on your product pack tells your customers you are offering a product of quality, proven efficacy, clinical validation and innovation.

FOR FURTHER INFORMATION ABOUT LIPISPERSE® OR TO DISCUSS HOW LIPISPERSE® CAN BENEFIT YOU CONTACT:



Pharmako Biotechnologies
T +61 2 9451 0099
E enquiries@pharmako.com.au
W www.pharmako.com.au



LipiSpense® is a patented technology and a registered trade mark owned exclusively by Pharmako Biotechnologies Pty Ltd.

© 2022 Pharmako Biotechnologies Pty Ltd. Please note this information is of an informative nature only, provided for customers globally and it may contain statements, claims or product classifications that do not comply with laws and regulations applicable to your country. The claims made are in reference to ingredients only, and not to finished products. You are responsible for all legal compliance for the finished products containing the ingredients and ensuring that the destination of the products and the claims made for them are lawful.